AROA Business Update
Filed with ASX · · 3 pages · English
• The US Centers for Medicaid and Medicare Services (CMS) has implemented a single reimbursement rate of US$127.14 per square centimetre for outpatient skin substitutes, leaving Symphony well positioned for outpatient adoption. • AROA’s Symphony Randomised Control Trial (RCT), designed to assess efficacy in treating diabetic foot ulcers, has concluded, and will be published in FY27. Myriad™ • In J
In the deck
Earlier from Aroa Biosurgery
- Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
- Aroa Biosurgery H1 FY26 Results
- Appendix 4D and Half Year Report
- September 2025 Quarterly Report and Appendix 4C
- First clinical evidence published on AROA's ENIVO™ system for surgical dead space management.
Later from Aroa Biosurgery
- AROA Business Update Presentation
- Symphony Randomised Control Trial Complete
- ARX FY26 Preliminary Results
- FY26 Appendix 4E and Full Year Results
- FY26 Full Year Results Presentation
Follow Aroa Biosurgery into a list and get an email when it puts out news.
Follow Aroa Biosurgery